Risks and benefits of phase 1 oncology trials, revisited
N Engl J Med
.
2005 Mar 3;352(9):930-2.
doi: 10.1056/NEJMe058007.
Authors
Razelle Kurzrock
,
Robert S Benjamin
PMID:
15745986
DOI:
10.1056/NEJMe058007
No abstract available
Publication types
Comment
Editorial
MeSH terms
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Clinical Trials, Phase I as Topic* / ethics
Dose-Response Relationship, Drug
Humans
Neoplasms / drug therapy*
Risk Assessment
Substances
Antineoplastic Agents